← Leaderboards
William Mc Culloch
Ciclomed, Llc
$956,317
Attributed
$1,912,633
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $976.4K · FY2020–21$1M$750K$500K$250K$0
'20
'21
Funding mix
By agency
NIH$1,912,633 · 1
By mechanism
R44$1,912,633 · 1
Top collaborators
- Scott James Weir2 shared
Others in their field
Other Emerging Leaders on “Aftercare”
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,888,963
- Bronwen Shaw · Medical College Of Wisconsin$19,182,557
- Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai$13,559,983
- Ki Young Chung · Prisma Health - Upstate$8,495,983
- Deanna A Kulpa · Emory University$8,444,989
Research focus
AftercareAmerican Cancer SocietyBaseBiobankBiological MarkersBladder NeoplasmBladder UrotheliumCancer Cell LineCancer CenterCancer PatientCd8b1 GeneCell ProliferationCellsChemical CarcinogenChemotherapyCirculating BiomarkersCisplatinClinical PharmacologyClinical TrialsCohort StudiesConsentDatabasesDesignAffect
Grant awards (2)
Development of Ciclopirox Prodrug as a Novel Systemic Treatment for High-Risk Non-Muscle Invasive Bladder Cancer$976,393
R44 · FY2021 · CA · contact PI
Development of Ciclopirox Prodrug as a Novel Systemic Treatment for High-Risk Non-Muscle Invasive Bladder Cancer$936,240
R44 · FY2020 · CA · contact PI